– November 1, 2008
November 1, 2008
View Issues
-
Intensive Treatment and Autologous Transplant for Mantle Cell Lymphoma
Long-term disease control remains an elusive target for mantle cell lymphoma (MCL), even after aggressive therapy. -
Erythropoiesis-stimulating Agents and Myeloma: Bad News or No News?
In a retrospective analysis of 323 patients with multiple myeloma, of which 169 patients received one or another form of ESA for treatment of disease or treatment-associated anemia, multivariate analysis, using a proportional hazard model, indicated worse progression-free and overall survival associated with ESA treatment. -
XELOX for Second-Line Pancreatic Cancer
Capecitabine and oxaliplatin were used in combination for patients with advanced pancreatic cancer refractory to first-line gemcitabine. -
Sorafenib and Hypertension: Meta-Analysis
Sorafenib is a multikinase inhibitor approved for treatment of renal cell and hepatocellular carcinomas. -
Pharmacology Watch
Ongoing safety review of tiotropium; raloxifene reduces the risk of endometrial cancer; one-day treatment with famciclovir may be as effective as 3-day treatment with valacyclovir; new Clinical Practice Guideline from the American College of Physicians regarding pharmacologic treatment for low bone density and osteoporosis; FDA Actions. -
Clinical Briefs in Primary Care supplement